XML 27 R17.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Disaggregation Of Revenue (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Net Revenue	$ 14,948,579	$ 14,592,254
United States [Member]
Net Revenue	12,976,000
Rest Of World [Member]
Net Revenue	1,972,000
Concentrate Products [Member]
Net Revenue	14,880,000
Concentrate Products [Member] \| United States [Member]
Net Revenue	12,976,000
Concentrate Products [Member] \| Rest Of World [Member]
Net Revenue	1,904,000
Transferred at Point in Time [Member] \| License Fee [Member] \| Concentrate Products [Member]
Net Revenue	504,000
Transferred at Point in Time [Member] \| License Fee [Member] \| Concentrate Products [Member] \| United States [Member]
Net Revenue	504,000
Transferred at Point in Time [Member] \| Producet Sales [Member] \| Concentrate Products [Member]
Net Revenue	14,376,000
Transferred at Point in Time [Member] \| Producet Sales [Member] \| Concentrate Products [Member] \| United States [Member]
Net Revenue	12,472,000
Transferred at Point in Time [Member] \| Producet Sales [Member] \| Concentrate Products [Member] \| Rest Of World [Member]
Net Revenue	1,904,000
Transferred over Time [Member] \| License Fee [Member] \| Drug Revenue [Member]
Net Revenue	68,000
Transferred over Time [Member] \| License Fee [Member] \| Drug Revenue [Member] \| Rest Of World [Member]
Net Revenue	$ 68,000